Kashiv BioSciences has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals for a complex peptide product, strengthening both companies’ presence across Europe, the UK and India.
Under the agreement, Intas will commercialise the product in India, while its UK-based subsidiary, Accord Healthcare, will handle commercialisation and distribution across pan-European and UK markets. Kashiv will be responsible for regulatory registration, manufacturing and supply of the product for all covered regions.
The partnership brings together Kashiv’s vertically integrated biopharmaceutical capabilities with Intas’ established multinational footprint and Accord Healthcare’s strong European market presence. The agreement is expected to support broader access to complex peptide therapies and expand the companies’ combined portfolios in key global markets.
The collaboration reflects a shared focus on improving patient access to high-quality and affordable treatments, while addressing unmet medical needs across diverse healthcare systems in Europe, the UK and India.
